Tumor Genomics Did Not Replace mFOLFIRINOX as Standard Adjuvant PDAC Therapy
Genomic profiling from PRODIGE-24/CCTG PA6 found prognostic PurIST effects, but no biomarker strong enough to displace mFOLFIRINOX in resected PDAC.
This section contains the website’s posts.